Novavax Reports Q1 2026 Earnings with Revenue Drop and Strategic Updates
Novavax (NVAX) reported Q1 2026 earnings with total revenue of $140 million, a 79% decrease from the prior year, primarily due to the absence of noncash Nuvaxovid product sales. Supply sales increased 139% to $33 million, driven by higher demand for Matrix-M adjuvant and collaboration with Sanofi. Licensing royalties and other revenue rose 116% to $97 million.
Topics: cash position expenses guidance net loss revenue